{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:10:07Z","timestamp":1757628607513,"version":"3.44.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Major (Key) Public Welfare Projects of Jinhua Science and Technology Bureau of Zhejiang Province","award":["2021-3-111"],"award-info":[{"award-number":["2021-3-111"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-025-01674-w","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:53:20Z","timestamp":1741074800000},"page":"3971-3981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMEPA1 Binds NEDD4L to Inhibit the Malignant Progression of Multiple Myeloma by Inactivating Wnt\/\u03b2-Catenin Signaling"],"prefix":"10.1007","volume":"83","author":[{"given":"Shanshan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"1674_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7\u201333.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"1674_CR2","doi-asserted-by":"publisher","first-page":"204062072110661","DOI":"10.1177\/20406207211066173","volume":"13","author":"H Magen","year":"2022","unstructured":"Magen, H., Simchen, M. J., Erman, S., & Avigdor, A. (2022). Diagnosis and management of multiple myeloma during pregnancy: Case report, review of the literature, and an update on current treatments. Therapeutic Advances in Hematology, 13, 20406207211066173.","journal-title":"Therapeutic Advances in Hematology"},{"key":"1674_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12\u201349.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"1674_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Pawlyn, C., & Yong, K. L. (2021). Multiple myeloma. Lancet, 397, 410\u2013427.","journal-title":"Lancet"},{"key":"1674_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian, H., Wildes, T. M., Vij, R., Pianko, M. J., Major, A., & Fiala, M. A. (2023). Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer Journal, 13, 76.","journal-title":"Blood Cancer Journal"},{"key":"1674_CR6","first-page":"430","volume":"36","author":"SA Holstein","year":"2022","unstructured":"Holstein, S. A. (2022). Current frontline treatment of multiple myeloma. Oncology (Williston Park, N.Y.), 36, 430\u2013441.","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"1674_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/geno.2000.6214","volume":"66","author":"LL Xu","year":"2000","unstructured":"Xu, L. L., Shanmugam, N., Segawa, T., Sesterhenn, I. A., McLeod, D. G., Moul, J. W., & Srivastava, S. (2000). A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics, 66, 257\u2013263.","journal-title":"Genomics"},{"key":"1674_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/biom10091221","volume":"10","author":"S Sharad","year":"2020","unstructured":"Sharad, S., Dobi, A., Srivastava, S., Srinivasan, A., & Li, H. (2020). PMEPA1 gene isoforms: A potential biomarker and therapeutic target in prostate cancer. Biomolecules, 10, 1221.","journal-title":"Biomolecules"},{"key":"1674_CR9","doi-asserted-by":"publisher","first-page":"101931","DOI":"10.1016\/j.mcp.2023.101931","volume":"72","author":"F Wen","year":"2023","unstructured":"Wen, F., Yang, S., Cai, W., Zhao, M., Qin, L., & Jiao, Z. (2023). Exploring the role of PMEPA1 in gastric cancer. Molecular and Cellular Probes, 72, 101931.","journal-title":"Molecular and Cellular Probes"},{"key":"1674_CR10","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1074\/jbc.RA117.000972","volume":"293","author":"Y Du","year":"2018","unstructured":"Du, Y., Liu, Y., Xu, Y., Juan, J., Zhang, Z., Xu, Z., Cao, B., Wang, Q., Zeng, Y., & Mao, X. (2018). The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Journal of Biological Chemistry, 293, 5847\u20135859.","journal-title":"Journal of Biological Chemistry"},{"key":"1674_CR11","doi-asserted-by":"publisher","first-page":"1291773","DOI":"10.3389\/fphar.2023.1291773","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang, M., Zhang, Z., Tian, X., Zhang, E., Wang, Y., Tang, J., & Zhao, J. (2023). NEDD4L in human tumors: regulatory mechanisms and dual effects on anti-tumor and pro-tumor. Frontiers in Pharmacology, 14, 1291773.","journal-title":"Frontiers in Pharmacology"},{"key":"1674_CR12","doi-asserted-by":"publisher","first-page":"774648","DOI":"10.3389\/fonc.2021.774648","volume":"11","author":"S Xie","year":"2021","unstructured":"Xie, S., Xia, L., Song, Y., Liu, H., Wang, Z. W., & Zhu, X. (2021). Insights into the biological role of NEDD4L E3 ubiquitin ligase in human cancers. Frontiers in Oncology, 11, 774648.","journal-title":"Frontiers in Oncology"},{"key":"1674_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04629-8","volume":"13","author":"X Huang","year":"2022","unstructured":"Huang, X., Cao, W., Yao, S., Chen, J., Liu, Y., Qu, J., Li, Y., Han, X., He, J., Huang, H., Zhang, E., & Cai, Z. (2022). NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma. Cell Death and Disease, 13, 197.","journal-title":"Cell Death and Disease"},{"key":"1674_CR14","doi-asserted-by":"publisher","first-page":"e0225913","DOI":"10.1371\/journal.pone.0225913","volume":"14","author":"KC Chen","year":"2019","unstructured":"Chen, K. C., Chen, P. H., Ho, K. H., Shih, C. M., Chou, C. M., Cheng, C. H., & Lee, C. C. (2019). IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt\/\u03b2-catenin pathway. PLoS One, 14, e0225913.","journal-title":"PLoS One"},{"key":"1674_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cellsig.2019.03.016","volume":"59","author":"R Amalia","year":"2019","unstructured":"Amalia, R., Abdelaziz, M., Puteri, M. U., Hwang, J., Anwar, F., Watanabe, Y., & Kato, M. (2019). TMEPAI\/PMEPA1 inhibits Wnt signaling by regulating \u03b2-catenin stability and nuclear accumulation in triple negative breast cancer cells. Cellular Signalling, 59, 24\u201333.","journal-title":"Cellular Signalling"},{"key":"1674_CR16","first-page":"9932","volume":"13","author":"Y Yuan","year":"2021","unstructured":"Yuan, Y., Guo, M., Gu, C., & Yang, Y. (2021). The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). American Journal of Translational Research, 13, 9932\u20139949.","journal-title":"American Journal of Translational Research"},{"key":"1674_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.), 25, 402\u2013408.","journal-title":"Methods (San Diego, Calif.)"},{"key":"1674_CR18","doi-asserted-by":"publisher","first-page":"155495","DOI":"10.1016\/j.cyto.2021.155495","volume":"142","author":"H Chen","year":"2021","unstructured":"Chen, H., Zhao, Y., Zhang, J., Xie, Y., & Jin, M. (2021). Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt\/\u03b2-catenin\/Versican signaling pathway. Cytokine, 142, 155495.","journal-title":"Cytokine"},{"key":"1674_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12253-017-0247-x","volume":"24","author":"MS Karbyshev","year":"2018","unstructured":"Karbyshev, M. S., Grigoryeva, E. S., Volkomorov, V. V., Kremmer, E., Huber, A., Mitrofanova, I. V., Kaigorodova, E. V., Zavyalova, M. V., Kzhyshkowska, J. G., Cherdyntseva, N. V., & Choynzonov, E. L. (2018). Development of novel monoclonal antibodies for evaluation of transmembrane prostate androgen-induced protein 1 (TMEPAI) expression patterns in gastric cancer. Pathology Oncology Research, 24, 427\u2013438.","journal-title":"Pathology Oncology Research"},{"key":"1674_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2478\/s11658-007-0009-y","volume":"12","author":"YS Hirokawa","year":"2007","unstructured":"Hirokawa, Y. S., Takagi, A., Uchida, K., Kozuka, Y., Yoneda, M., Watanabe, M., & Shiraishi, T. (2007). High level expression of STAG1\/PMEPA1 in an androgen-independent prostate cancer PC3 subclone. Cellular & Molecular Biology Letters, 12, 370\u2013377.","journal-title":"Cellular & Molecular Biology Letters"},{"key":"1674_CR21","doi-asserted-by":"publisher","first-page":"1298660","DOI":"10.3389\/fonc.2023.1298660","volume":"13","author":"Q Zhu","year":"2023","unstructured":"Zhu, Q., Wang, Y., Liu, Y., Yang, X., & Shuai, Z. (2023). Prostate transmembrane androgen inducible protein 1 (PMEPA1): Regulation and clinical implications. Frontiers in Oncology, 13, 1298660.","journal-title":"Frontiers in Oncology"},{"key":"1674_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41388-019-1050-9","volume":"39","author":"J Ji","year":"2020","unstructured":"Ji, J., Ding, K., Luo, T., Xu, R., Zhang, X., Huang, B., Chen, A., Zhang, D., Miletic, H., Bjerkvig, R., Thorsen, F., Wang, J., & Li, X. (2020). PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1. Oncogene, 39, 1125\u20131139.","journal-title":"Oncogene"},{"key":"1674_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jb\/mvy059","volume":"164","author":"S Itoh","year":"2018","unstructured":"Itoh, S., & Itoh, F. (2018). TMEPAI family: involvement in regulation of multiple signalling pathways. Journal of Biochemistry, 164, 195\u2013204.","journal-title":"Journal of Biochemistry"},{"key":"1674_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/CBM-200966","volume":"31","author":"B Tan","year":"2021","unstructured":"Tan, B., Chen, Y., Xia, L., Yu, X., Peng, Y., Zhang, X., & Yang, Z. (2021). PMEPA1 facilitates non-small cell lung cancer progression via activating the JNK signaling pathway. Cancer Biomarkers: Section A of Disease Markers, 31, 203\u2013210.","journal-title":"Cancer Biomarkers: Section A of Disease Markers"},{"key":"1674_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.amjms.2021.04.002","volume":"362","author":"M Song","year":"2021","unstructured":"Song, M., Zhou, B., Li, B., & Tian, L. (2021). PMEPA1 stimulates the proliferation, colony formation of pancreatic cancer cells via the MAPK signaling pathway. The American Journal of the Medical Sciences, 362, 291\u2013296.","journal-title":"The American Journal of the Medical Sciences"},{"key":"1674_CR26","doi-asserted-by":"publisher","first-page":"705086","DOI":"10.3389\/fimmu.2021.705086","volume":"12","author":"D Qiu","year":"2021","unstructured":"Qiu, D., Hu, J., Hu, J., Yu, A., Othmane, B., He, T., Ding, J., Cheng, X., Ren, W., Tan, X., Yu, Q., Chen, J., & Zu, X. (2021). PMEPA1 is a prognostic biomarker that correlates with cell malignancy and the tumor microenvironment in bladder cancer. Frontiers in Immunology, 12, 705086.","journal-title":"Frontiers in Immunology"},{"key":"1674_CR27","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.18632\/oncotarget.3526","volume":"6","author":"H Li","year":"2015","unstructured":"Li, H., Mohamed, A. A., Sharad, S., Umeda, E., Song, Y., Young, D., Petrovics, G., McLeod, D. G., Sesterhenn, I. A., Sreenath, T., Dobi, A., & Srivastava, S. (2015). Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget, 6, 15137\u201315149.","journal-title":"Oncotarget"},{"key":"1674_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajur.2015.11.002","volume":"3","author":"AM Blee","year":"2016","unstructured":"Blee, A. M., & Huang, H. (2016). PMEPA1 guards against TGF-\u03b2-mediated prostate cancer bone metastasis. Asian Journal of Urology, 3, 1\u20133.","journal-title":"Asian Journal of Urology"},{"key":"1674_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/mc.1063","volume":"32","author":"FK Rae","year":"2001","unstructured":"Rae, F. K., Hooper, J. D., Nicol, D. L., & Clements, J. A. (2001). Characterization of a novel gene, STAG1\/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Molecular Carcinogenesis, 32, 44\u201353.","journal-title":"Molecular Carcinogenesis"},{"key":"1674_CR30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.ejhg.5200747","volume":"9","author":"H Chen","year":"2001","unstructured":"Chen, H., Ross, C. A., Wang, N., Huo, Y., MacKinnon, D. F., Potash, J. B., Simpson, S. G., McMahon, F. J., DePaulo, Jr, J. R., & McInnis, M. G. (2001). NEDD4L on human chromosome 18q21 has multiple forms of transcripts and is a homologue of the mouse Nedd4-2 gene. European Journal of Human Genetics, 9, 922\u2013930.","journal-title":"European Journal of Human Genetics"},{"key":"1674_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12094-022-02933-5","volume":"25","author":"R Feng","year":"2023","unstructured":"Feng, R., Li, Z., Ge, G., Wang, C., Jia, Y., & Ouyang, J. (2023). NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin-proteasome pathway. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 25, 243\u2013255.","journal-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"key":"1674_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/15384047.2022.2054244","volume":"23","author":"G Zhang","year":"2022","unstructured":"Zhang, G., Zhao, X., & Liu, W. (2022). NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation. Cancer Biology & Therapy, 23, 243\u2013253.","journal-title":"Cancer Biology & Therapy"},{"key":"1674_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbrc.2019.04.001","volume":"513","author":"X Wang","year":"2019","unstructured":"Wang, X., Duan, J., Fu, W., Yin, Z., Sheng, J., Lei, Z., & Wang, H. (2019). Decreased expression of NEDD4L contributes to NSCLC progression and metastasis. Biochemical and Biophysical Research Communications, 513, 398\u2013404.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"1674_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.leu.2405044","volume":"22","author":"N Booken","year":"2008","unstructured":"Booken, N., Gratchev, A., Utikal, J., Weiss, C., Yu, X., Qadoumi, M., Schmuth, M., Sepp, N., Nashan, D., Rass, K., T\u00fcting, T., Assaf, C., Dippel, E., Stadler, R., Klemke, C. D., & Goerdt, S. (2008). S\u00e9zary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia, 22, 393\u2013399.","journal-title":"Leukemia"},{"key":"1674_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/iep.12051","volume":"95","author":"Y Kito","year":"2014","unstructured":"Kito, Y., Bai, J., Goto, N., Okubo, H., Adachi, Y., Nagayama, T., & Takeuchi, T. (2014). Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma. International Journal of Experimental Pathology, 95, 24\u201328.","journal-title":"International Journal of Experimental Pathology"},{"key":"1674_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2613.2010.00740.x","volume":"92","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi, T., Adachi, Y., Nagayama, T., & Furihata, M. (2011). Nedd4L modulates the transcription of metalloproteinase-1 and -13 genes to increase the invasive activity of gallbladder cancer. International Journal of Experimental Pathology, 92, 79\u201386.","journal-title":"International Journal of Experimental Pathology"},{"key":"1674_CR37","doi-asserted-by":"publisher","first-page":"2251696","DOI":"10.1080\/21655979.2023.2251696","volume":"14","author":"A Dev","year":"2023","unstructured":"Dev, Jr., A., Vachher, M., & Prasad, C. P. (2023). \u03b2-catenin inhibitors in cancer therapeutics: intricacies and way forward. Bioengineered, 14, 2251696.","journal-title":"Bioengineered"},{"key":"1674_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021). Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy, 6, 307.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"1674_CR39","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019). Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia, 33, 1063\u20131075.","journal-title":"Leukemia"},{"key":"1674_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., & Wang, X. (2020). Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. Journal of Hematology & Oncology, 13, 165.","journal-title":"Journal of Hematology & Oncology"},{"key":"1674_CR41","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1074\/jbc.M112.433185","volume":"288","author":"Y Ding","year":"2013","unstructured":"Ding, Y., Zhang, Y., Xu, C., Tao, Q. H., & Chen, Y. G. (2013). HECT domain-containing E3 ubiquitin ligase NEDD4L negatively regulates Wnt signaling by targeting dishevelled for proteasomal degradation. Journal of Biological Chemistry, 288, 8289\u20138298.","journal-title":"Journal of Biological Chemistry"},{"key":"1674_CR42","doi-asserted-by":"publisher","first-page":"e81514","DOI":"10.1371\/journal.pone.0081514","volume":"8","author":"JP Tanksley","year":"2013","unstructured":"Tanksley, J. P., Chen, X., & Coffey, R. J. (2013). NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. PLoS One, 8, e81514.","journal-title":"PLoS One"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-025-01674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-025-01674-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-025-01674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:03:20Z","timestamp":1757498600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-025-01674-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1007\/s12013-025-01674-w","relation":{},"ISSN":["1559-0283"],"issn-type":[{"type":"electronic","value":"1559-0283"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"9 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}